Related Experiment Video
Updated: May 1, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Factors associated with drug-resistant epilepsy in adults from Southern Kazakhstan
Gulzira Baimakhanova1, Nursultan Nurdinov1, Gulnaz Nuskabayeva1
1Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkistan, Kazakhstan.
Introduction:
The prevalence of drug-resistant epilepsy (DRE) among epilepsy patients has not decreased despite better diagnostic methods and treatment options because it affects approximately one-third of all epilepsy patients. The research aims to identify which clinical patterns and social characteristics contribute to drug resistance.
Methods:
This retrospective analytical cross-sectional study included 300 patients with epilepsy in Southern Kazakhstan. The participants received their drug resistance status through ILAE criteria, which classified them into drug-sensitive (DSE) or drug-resistant groups. Patient data was studied through clinical and socio-demographic evaluations, EEG and MRI assessments, and MoCA cognitive performance tests.
Results:
The research discovered drug-resistant epilepsy in 37% of participants. The DRE patients were 35 ± 12 years old at the time of study, while DSE patients were 39 ± 15 years old (p = 0.023). The development of DRE became more likely when patients experienced their first seizure at a young age and when they had multiple seizures throughout the day (p < 0.01). The presence of MRI abnormalities increased the risk of drug resistance by 2.42 times (95% CI: 1.3-4.23) when compared to drug-sensitive epilepsy patients (p = 0.002).
Conclusion:
The study revealed that early seizure onset, prolonged duration, severe seizures, brain imaging abnormalities, and lower cognitive performance are related to DRE.
More Related Videos
Related Concept Videos
Drug Toxicity: Risk factors
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

